1.Alternative Name:CD66e
2.Target:CEACAM5
3.Source:Cynomolgus CEACAM5 was expressed from HEK293 with human IgG1 FC at the C-terminal,XP_005589491.1(Gln35-Ala688).
4.Sequence:XP_005589491.1
5.Protein structure:XP_005589491.1hFC
6.Molecular Characterization:The protein has a calculated MW of 97kDa.The reducing (R) heterodimer protein migrates as 140-170 kDa due to glycosylation
7.Purity:SDS-PAGE>95%，SEC>95%
8.Reconstitution:sterile H2O
9.Endotoxin:<1EU/mg
10.Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.
11.SDS-PAGE

Determined by SDS-PAGE, the purity of the protein is greater than 90%.

12.SEC-HPLC

        Determined by SEC-HPLC, the purity of the protein is greater than 95%.

13.ELISA

When Recombinant Cynomolgus CEACAM5/hFC Protein is immobilized at 2μg/mL (100 μL/well), the concentration of Anti-Human CEACAM5(tusamitamab) that produces 50% of the optimal binding response is approximately 0.7 ug/ml.

14.ELISA

When Recombinant Cynomolgus CEACAM5/hFC Protein is immobilized at 2μg/mL (100 μL/well), the concentration of Anti-Human CEACAM5(tusamitamab) that produces 50% of the optimal binding response is approximately 0.7 ug/ml.

15.Note：For research use only .